One-Year Outcomes of 1 + pro re nata versus 3 + pro re nata Intravitreal Aflibercept Injection for Neovascular Age-Related Macular Degeneration

<b><i>Purpose:</i></b> We compared 1-year outcomes of 1 + pro re nata (PRN) versus 3 + PRN of intravitreal aflibercept injection (IAI) for age-related macular degeneration (AMD). <b><i>Methods:</i></b> Forty-two eyes with naïve AMD received 3 + PRN IAI treatment and 47 eyes with naïve AMD received 1 + PRN IAI treatment. Visual acuity (VA), central retinal thickness (CRT), and central choroidal thickness (CCT) and number of administered IAIs during 12 months were compared. <b><i>Results:</i></b> VAs improved, and CRTs reduced significantly at any given month from baseline in both groups (<i>p</i> < 0.01, respectively). CCT reduced significantly at 3 months in the 3 + PRN group (<i>p</i> = 0.024) but not in the 1 + PRN group. The 1 + PRN group received fewer injections than the 3 + PRN group (<i>p</i> < 0.01). <b><i>Conclusions:</i></b> Aflibercept leads to equivalent VA and morphologic retinal improvement without administering 3 injections.